BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market
Executive Summary
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
You may also be interested in...
Pharvaris’s Oral HAE Prevention Data May Threaten BioCryst’s Orladeyo
The Swiss firm reported that its oral bradykinin B2 receptor antagonist reduced monthly hereditary angioedema attacks by 84.5% compared with placebo, suggesting biologic-like efficacy with an oral drug.
CSL Seeks Disruption Of HAE Space With Monthly Prevention Product
Based on top-line Phase III data for garadacimab, CSL is preparing to submit the Factor XIIa inhibitor for US FDA approval for monthly prophylaxis of hereditary angioedema and expand the firm’s HAE franchise.
BioCryst Halts Trials For BCX9930 Due To Safety Concerns
Biotech stops enrollment in three Phase II studies of oral Factor D inhibitor BCX9930 after seeing elevated creatinine levels. The halt is voluntary, and enrolled patients can continue dosing, BioCryst says.